Do weight-loss drugs really save money? Mostly only for high earners
The class of medications known as GLP-1 receptor agonists, sold under brand names such as Wegovy and Ozempic, has transformed weight management in recent years. But a new analysis suggests the financial upside these drugs are often assumed to deliver may be out of reach for most of the people taking them.
The analysis, carried out by the consultancy Baringa, finds that after covering the roughly £1,200 annual cost of GLP-1 medication, a person needs approximately £100,000 a year in discretionary income to see a net saving on their grocery bill.
The logic is straightforward, if sobering: these appetite-suppressing drugs reduce how much food a person eats, which trims grocery spending somewhat. But for low- and middle-income households already working with tight food budgets, the savings generated simply aren't large enough to offset the cost of the medication itself.
Researchers describe the pattern as a 'tax on being thin' — someone who wants the health benefits the drugs offer, including weight loss, better blood sugar control and reduced cardiovascular risk, ends up carrying an additional financial burden purely because they can afford to access treatment in the first place.
The finding deepens existing inequalities in access to obesity treatment. Lower-income patients without insurance coverage, or living under health systems that don't reimburse GLP-1 medication, face a double disadvantage: paying out of pocket for the drug and failing to see savings elsewhere to offset it.
Specialists stress the analysis doesn't call the drugs' medical value into question — only the simplified narrative that these medications 'pay for themselves' financially, which the data suggests doesn't hold for most people. The real value of GLP-1 drugs, they note, lies in long-term health outcomes and the prevention of costly medical complications.
Some health economists argue that focusing narrowly on grocery savings misses much of the picture. Given the treatment costs associated with obesity-related type 2 diabetes, high blood pressure and joint problems, GLP-1 medication could still reduce total costs to both health systems and individuals over the long run.
Those longer-term savings, however, depend on a patient being able to afford the drug consistently and stay on treatment without interruption. Patients who stop taking the medication because of cost tend to regain the weight, largely erasing the drug's longer-term benefits.
Public health advocates say the findings strengthen the case for expanding access to GLP-1 medication through policy. Broader insurance coverage or lower prices, they argue, would stop the drugs from functioning as an option available mainly to people who are already financially comfortable.
For now, the analysis lays out a simple but consequential truth: GLP-1 drugs can offer life-changing health benefits for many people, but marketing them as a financially self-funding investment doesn't reflect the real budgets most patients are working with.
Read next
Why vitamin D deficiency turns far more dangerous when belly fat is involved
A large study of more than 5,500 adults over 50 found that abdominal obesity combined with vitamin D deficiency was linked to a 123% higher risk of death within six years. Researchers say the two conditions appear to feed into each other, creating a dangerous cycle rather than simply adding independent risks.
Can drinking orange juice every day really change your genes
New research suggests regularly drinking orange juice may influence the activity of thousands of genes tied to inflammation, blood pressure, metabolism and blood sugar control. Scientists suspect natural citrus compounds such as hesperidin, along with benefits to the gut microbiome, may be behind the effect.
US recalls 1.6m dozen eggs as salmonella outbreak sickens dozens
Nearly 1.6 million dozen eggs have been recalled across the US south and south-west after being linked to a salmonella outbreak that has sickened nearly 100 people, one of the largest recorded foodborne illness incidents in recent US history. The FDA has classified the recall at its highest risk level.
Methadone clinics: what two years of looser US rules actually changed
It has been two years since US regulators relaxed the rigid rules governing methadone clinics that treat opioid addiction. Some clinics have used the new flexibility to ease access for patients, but many have changed little from their older, stricter routines.
Eclipse eye damage: how to tell if the sun hurt your vision
An eye surgeon says fewer people have sought treatment for eye damage after the latest solar eclipse than after the UK's last total eclipse in 1999. Ophthalmologists explain what solar retinopathy looks like, why it is often painless, and when to seek care.